A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19

计划入组 344 人 · 首次发布于 2025 年 10 月 29 日

The Prevalence of Hyper-Lp(a)-Emia in the PMMHRI-Lp(a) Registry

计划入组 2,000 人 · 首次发布于 2024 年 9 月 24 日

A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)

计划入组 42 人 · 首次发布于 2014 年 9 月 16 日

LP-342

Sugaheal variant

LP-922056

Janssen LP

United States

AstraZeneca LP

United States

Covidien LP

United States

Moderna Submits LP.8.1 Targeting COVID-19 Vaccine to FDA for 2025-2026 Season

Trump Demands COVID-19 Drug Data Transparency as CDC Leadership Crisis Deepens

COVID-19 Boosters Reduce Hospitalizations and Deaths by Up to 64% in Large Veterans Study